Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19176519 | 0.95 | TDP1 (0.36) | TDP1L3MBTL1CYSLTR2CYSLTR1NR1I2 | |
| SCHEMBL26304408 | 0.91 | KDM4E (0.38) | TDP1L3MBTL1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL23869499 | 0.84 | TDP1 (0.37) | TDP1L3MBTL1CYSLTR2CYSLTR1NR1I2 | |
| SCHEMBL18469769 | 0.84 | KDM4E (0.37) | KDM4ESMN1; SMN2LOXL2 | |
| SCHEMBL18800045 | 0.83 | TDP1 (0.36) | TDP1L3MBTL1KCNA5KCNH2LMNA | |
| SCHEMBL25150545 | 0.83 | TDP1 (0.38) | TDP1L3MBTL1KDM4ESMN1; SMN2CYSLTR2 | |
| SCHEMBL18855230 | 0.80 | TDP1 (0.38) | TDP1L3MBTL1KDM4ECYSLTR2CYSLTR1 | |
| SCHEMBL18635979 | 0.80 | TDP1 (0.38) | TDP1L3MBTL1KDM4ECYSLTR2CYSLTR1 | |
| SCHEMBL21100836 | 0.79 | HTR1A (0.36) | TDP1L3MBTL1KDM4ESMN1; SMN2CYSLTR2 | |
| SCHEMBL23219779 | 0.79 | NR1I2 (0.38) | TDP1L3MBTL1CYSLTR2CYSLTR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TDP1 2415/4885L3MBTL1 3899/4885KDM4E 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.